








 $\text{Clinic'n'Cell } \exists x \text{-vivo clinical trials} \texttt{®}$



adipo CYCR® for burning



Adipocyte





UNIVERSITÉ DE ROUEN


Clinic'n'Cell Ex-vivo clinical trials®

Protected and licensed











etabolic and anti-weight gain protective properties of human enriched serum following **adipoCYNAR**® absorption.

Protected and licensed protocol: Clinic'n cell results from an innovative Ex Vivo Clinical Trial.

Rapid and relevant scientific evidences regarding the biological activity of **adipoCYNAR®** through human metabolism.



Phase 1:

- adipoCYNAR® administration to volunteers.
- Determination of maximum absorption of **adipoCYNAR®** in venous blood: 100 minutes after ingestion.

Phase 2:

- Serum collected at peak absorption.
- Incubation of serum with targeted primary human adipocytes cells.
- Determination of biological activities.









Relevance of results:

Cells are treated with the enriched human serum from adipoCYNAR® and not directly with the extracts.




Human serum enriched with adipoCYNAR® metabolites




Human serum enriched with **adipo**CYNAR® metabolites





significantly limited the intracelullar lipid accumulation by -24% in differentiated adipocytes



significantly limited the intracelullar triglyceride accumulation by -54% in differentiated adipocytes





Conclusions

The metabolites of

$adipoCYNAR^{\mathbb{R}}$

limit the ability of primary human adipocytes to respond to culture conditions mimicking an obesogenic content that results in :

- **Decrease** capacity to store fat
- Reduction of intracellular lipid accumulation
 by -24%
- Reduction of intracellular triglyceride accumulation
 by -54%

